Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, in Parkinson's disease
Identifieur interne :
001775 ( PascalFrancis/Curation );
précédent :
001774;
suivant :
001776
Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, in Parkinson's disease
Auteurs : P. Limousin [
France] ;
P. Pollak [
France] ;
J. P. Pfeffen ;
C. L. Tournier-Gervason [
France] ;
R. Dubuis ;
J. E. Perret [
France]
Source :
-
Clinical neuropharmacology [ 0362-5664 ] ; 1995.
RBID : Pascal:95-0422394
Descripteurs français
- Pascal (Inist)
- Antiparkinsonien,
Inhibiteur enzyme,
Association médicamenteuse,
Chimiothérapie,
Efficacité traitement,
Homme,
Voie orale,
Parkinson maladie,
Etude double insu,
Placebo,
Tolcapone,
Dopa,
Bensérazide,
Catechol methyltransferase.
- Wicri :
English descriptors
- KwdEn :
- Antiparkinson agent,
Chemotherapy,
Dopa,
Double blind study,
Drug combination,
Enzyme inhibitor,
Human,
Oral administration,
Parkinson disease,
Placebo,
Treatment efficiency.
| pA |
| A01 | 01 | 1 | | @0 0362-5664 |
|---|
| A02 | 01 | | | @0 CLNEDB |
|---|
| A03 | | 1 | | @0 Clin. neuropharmacol. |
|---|
| A05 | | | | @2 18 |
|---|
| A06 | | | | @2 3 |
|---|
| A08 | 01 | 1 | ENG | @1 Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, in Parkinson's disease |
|---|
| A11 | 01 | 1 | | @1 LIMOUSIN (P.) |
|---|
| A11 | 02 | 1 | | @1 POLLAK (P.) |
|---|
| A11 | 03 | 1 | | @1 PFEFFEN (J. P.) |
|---|
| A11 | 04 | 1 | | @1 TOURNIER-GERVASON (C. L.) |
|---|
| A11 | 05 | 1 | | @1 DUBUIS (R.) |
|---|
| A11 | 06 | 1 | | @1 PERRET (J. E.) |
|---|
| A14 | 01 | | | @1 Joseph Fourier univ. Grenoble, dep. clin. biological neurosci. @2 38043 Grenoble @3 FRA @Z 1 aut. @Z 2 aut. @Z 4 aut. @Z 6 aut. |
|---|
| A20 | | | | @1 258-265 |
|---|
| A21 | | | | @1 1995 |
|---|
| A23 | 01 | | | @0 ENG |
|---|
| A43 | 01 | | | @1 INIST @2 16720 @5 354000050914840060 |
|---|
| A44 | | | | @0 0000 |
|---|
| A45 | | | | @0 27 ref. |
|---|
| A47 | 01 | 1 | | @0 95-0422394 |
|---|
| A60 | | | | @1 P |
|---|
| A61 | | | | @0 A |
|---|
| A64 | 01 | 1 | | @0 Clinical neuropharmacology |
|---|
| A66 | 01 | | | @0 USA |
|---|
| C02 | 01 | X | | @0 002B02B06 |
|---|
| C03 | 01 | X | FRE | @0 Antiparkinsonien |
|---|
| C03 | 01 | X | ENG | @0 Antiparkinson agent |
|---|
| C03 | 01 | X | SPA | @0 Antiparkinsoniano |
|---|
| C03 | 02 | X | FRE | @0 Inhibiteur enzyme |
|---|
| C03 | 02 | X | ENG | @0 Enzyme inhibitor |
|---|
| C03 | 02 | X | SPA | @0 Inhibidor enzima |
|---|
| C03 | 03 | X | FRE | @0 Association médicamenteuse |
|---|
| C03 | 03 | X | ENG | @0 Drug combination |
|---|
| C03 | 03 | X | SPA | @0 Asociación medicamentosa |
|---|
| C03 | 04 | X | FRE | @0 Chimiothérapie |
|---|
| C03 | 04 | X | ENG | @0 Chemotherapy |
|---|
| C03 | 04 | X | SPA | @0 Quimioterapia |
|---|
| C03 | 05 | X | FRE | @0 Efficacité traitement |
|---|
| C03 | 05 | X | ENG | @0 Treatment efficiency |
|---|
| C03 | 05 | X | SPA | @0 Eficacia tratamiento |
|---|
| C03 | 06 | X | FRE | @0 Homme |
|---|
| C03 | 06 | X | ENG | @0 Human |
|---|
| C03 | 06 | X | SPA | @0 Hombre |
|---|
| C03 | 07 | X | FRE | @0 Voie orale |
|---|
| C03 | 07 | X | ENG | @0 Oral administration |
|---|
| C03 | 07 | X | SPA | @0 Vía oral |
|---|
| C03 | 08 | X | FRE | @0 Parkinson maladie |
|---|
| C03 | 08 | X | ENG | @0 Parkinson disease |
|---|
| C03 | 08 | X | SPA | @0 Parkinson enfermedad |
|---|
| C03 | 09 | X | FRE | @0 Etude double insu |
|---|
| C03 | 09 | X | ENG | @0 Double blind study |
|---|
| C03 | 09 | X | SPA | @0 Estudio doble ciego |
|---|
| C03 | 10 | X | FRE | @0 Placebo |
|---|
| C03 | 10 | X | ENG | @0 Placebo |
|---|
| C03 | 10 | X | SPA | @0 Placebo |
|---|
| C03 | 11 | X | FRE | @0 Tolcapone @2 NK @2 FR |
|---|
| C03 | 12 | X | FRE | @0 Dopa @2 NK @2 FR |
|---|
| C03 | 12 | X | ENG | @0 Dopa @2 NK @2 FR |
|---|
| C03 | 12 | X | SPA | @0 Dopa @2 NK @2 FR |
|---|
| C03 | 13 | X | FRE | @0 Bensérazide @2 NK @2 FR |
|---|
| C03 | 14 | X | FRE | @0 Catechol methyltransferase @2 FE @4 INC |
|---|
| C07 | 01 | X | FRE | @0 Système nerveux pathologie |
|---|
| C07 | 01 | X | ENG | @0 Nervous system diseases |
|---|
| C07 | 01 | X | SPA | @0 Sistema nervioso patología |
|---|
| C07 | 02 | X | FRE | @0 Enzyme |
|---|
| C07 | 02 | X | ENG | @0 Enzyme |
|---|
| C07 | 02 | X | SPA | @0 Enzima |
|---|
| C07 | 03 | X | FRE | @0 Encéphale pathologie |
|---|
| C07 | 03 | X | ENG | @0 Cerebral disorder |
|---|
| C07 | 03 | X | SPA | @0 Encéfalo patología |
|---|
| C07 | 04 | X | FRE | @0 Système nerveux central pathologie |
|---|
| C07 | 04 | X | ENG | @0 Central nervous system disease |
|---|
| C07 | 04 | X | SPA | @0 Sistema nervosio central patología |
|---|
| C07 | 05 | X | FRE | @0 Maladie dégénérative |
|---|
| C07 | 05 | X | ENG | @0 Degenerative disease |
|---|
| C07 | 05 | X | SPA | @0 Enfermedad degenerativa |
|---|
| C07 | 06 | X | FRE | @0 Extrapyramidal syndrome |
|---|
| C07 | 06 | X | ENG | @0 Extrapyramidal syndrome |
|---|
| C07 | 06 | X | SPA | @0 Extrapiramidal síndrome |
|---|
| N21 | | | | @1 240 |
|---|
|
|---|
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001872
Links to Exploration step
Pascal:95-0422394
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, in Parkinson's disease</title>
<author><name sortKey="Limousin, P" sort="Limousin, P" uniqKey="Limousin P" first="P." last="Limousin">P. Limousin</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Joseph Fourier univ. Grenoble, dep. clin. biological neurosci.</s1>
<s2>38043 Grenoble</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14><country>France</country>
</affiliation><author><name sortKey="Pollak, P" sort="Pollak, P" uniqKey="Pollak P" first="P." last="Pollak">P. Pollak</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Joseph Fourier univ. Grenoble, dep. clin. biological neurosci.</s1>
<s2>38043 Grenoble</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14><country>France</country>
</affiliation><author><name sortKey="Pfeffen, J P" sort="Pfeffen, J P" uniqKey="Pfeffen J" first="J. P." last="Pfeffen">J. P. Pfeffen</name>
</author><author><name sortKey="Tournier Gervason, C L" sort="Tournier Gervason, C L" uniqKey="Tournier Gervason C" first="C. L." last="Tournier-Gervason">C. L. Tournier-Gervason</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Joseph Fourier univ. Grenoble, dep. clin. biological neurosci.</s1>
<s2>38043 Grenoble</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14><country>France</country>
</affiliation><author><name sortKey="Dubuis, R" sort="Dubuis, R" uniqKey="Dubuis R" first="R." last="Dubuis">R. Dubuis</name>
</author><author><name sortKey="Perret, J E" sort="Perret, J E" uniqKey="Perret J" first="J. E." last="Perret">J. E. Perret</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Joseph Fourier univ. Grenoble, dep. clin. biological neurosci.</s1>
<s2>38043 Grenoble</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14><country>France</country>
</affiliation><publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">95-0422394</idno>
<date when="1995">1995</date>
<idno type="stanalyst">PASCAL 95-0422394 INIST</idno>
<idno type="RBID">Pascal:95-0422394</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001872</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001775</idno>
</publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, in Parkinson's disease</title>
<author><name sortKey="Limousin, P" sort="Limousin, P" uniqKey="Limousin P" first="P." last="Limousin">P. Limousin</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Joseph Fourier univ. Grenoble, dep. clin. biological neurosci.</s1>
<s2>38043 Grenoble</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14><country>France</country>
</affiliation><author><name sortKey="Pollak, P" sort="Pollak, P" uniqKey="Pollak P" first="P." last="Pollak">P. Pollak</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Joseph Fourier univ. Grenoble, dep. clin. biological neurosci.</s1>
<s2>38043 Grenoble</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14><country>France</country>
</affiliation><author><name sortKey="Pfeffen, J P" sort="Pfeffen, J P" uniqKey="Pfeffen J" first="J. P." last="Pfeffen">J. P. Pfeffen</name>
</author><author><name sortKey="Tournier Gervason, C L" sort="Tournier Gervason, C L" uniqKey="Tournier Gervason C" first="C. L." last="Tournier-Gervason">C. L. Tournier-Gervason</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Joseph Fourier univ. Grenoble, dep. clin. biological neurosci.</s1>
<s2>38043 Grenoble</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14><country>France</country>
</affiliation><author><name sortKey="Dubuis, R" sort="Dubuis, R" uniqKey="Dubuis R" first="R." last="Dubuis">R. Dubuis</name>
</author><author><name sortKey="Perret, J E" sort="Perret, J E" uniqKey="Perret J" first="J. E." last="Perret">J. E. Perret</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Joseph Fourier univ. Grenoble, dep. clin. biological neurosci.</s1>
<s2>38043 Grenoble</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14><country>France</country>
</affiliation><series><title level="j" type="main">Clinical neuropharmacology</title>
<title level="j" type="abbreviated">Clin. neuropharmacol.</title>
<idno type="ISSN">0362-5664</idno>
<imprint><date when="1995">1995</date>
</imprint><seriesStmt><title level="j" type="main">Clinical neuropharmacology</title>
<title level="j" type="abbreviated">Clin. neuropharmacol.</title>
<idno type="ISSN">0362-5664</idno>
</seriesStmt><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson agent</term>
<term>Chemotherapy</term>
<term>Dopa</term>
<term>Double blind study</term>
<term>Drug combination</term>
<term>Enzyme inhibitor</term>
<term>Human</term>
<term>Oral administration</term>
<term>Parkinson disease</term>
<term>Placebo</term>
<term>Treatment efficiency</term>
</keywords><keywords scheme="Pascal" xml:lang="fr"><term>Antiparkinsonien</term>
<term>Inhibiteur enzyme</term>
<term>Association médicamenteuse</term>
<term>Chimiothérapie</term>
<term>Efficacité traitement</term>
<term>Homme</term>
<term>Voie orale</term>
<term>Parkinson maladie</term>
<term>Etude double insu</term>
<term>Placebo</term>
<term>Tolcapone</term>
<term>Dopa</term>
<term>Bensérazide</term>
<term>Catechol methyltransferase</term>
</keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0362-5664</s0>
</fA01><fA02 i1="01"><s0>CLNEDB</s0>
</fA02><fA03 i2="1"><s0>Clin. neuropharmacol.</s0>
</fA03><fA08 i1="01" i2="1" l="ENG"><s1>Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, in Parkinson's disease</s1>
</fA08><fA11 i1="01" i2="1"><s1>LIMOUSIN (P.)</s1>
</fA11><fA11 i1="02" i2="1"><s1>POLLAK (P.)</s1>
</fA11><fA11 i1="03" i2="1"><s1>PFEFFEN (J. P.)</s1>
</fA11><fA11 i1="04" i2="1"><s1>TOURNIER-GERVASON (C. L.)</s1>
</fA11><fA11 i1="05" i2="1"><s1>DUBUIS (R.)</s1>
</fA11><fA11 i1="06" i2="1"><s1>PERRET (J. E.)</s1>
</fA11><fA14 i1="01"><s1>Joseph Fourier univ. Grenoble, dep. clin. biological neurosci.</s1>
<s2>38043 Grenoble</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14><fA20><s1>258-265</s1>
</fA20><fA21><s1>1995</s1>
</fA21><fA23 i1="01"><s0>ENG</s0>
</fA23><fA43 i1="01"><s1>INIST</s1>
<s2>16720</s2>
<s5>354000050914840060</s5>
</fA43><fA44><s0>0000</s0>
</fA44><fA45><s0>27 ref.</s0>
</fA45><fA47 i1="01" i2="1"><s0>95-0422394</s0>
</fA47><fA64 i1="01" i2="1"><s0>Clinical neuropharmacology</s0>
</fA64><fA66 i1="01"><s0>USA</s0>
</fA66><fC02 i1="01" i2="X"><s0>002B02B06</s0>
</fC02><fC03 i1="01" i2="X" l="FRE"><s0>Antiparkinsonien</s0>
</fC03><fC03 i1="01" i2="X" l="ENG"><s0>Antiparkinson agent</s0>
</fC03><fC03 i1="01" i2="X" l="SPA"><s0>Antiparkinsoniano</s0>
</fC03><fC03 i1="02" i2="X" l="FRE"><s0>Inhibiteur enzyme</s0>
</fC03><fC03 i1="02" i2="X" l="ENG"><s0>Enzyme inhibitor</s0>
</fC03><fC03 i1="02" i2="X" l="SPA"><s0>Inhibidor enzima</s0>
</fC03><fC03 i1="03" i2="X" l="FRE"><s0>Association médicamenteuse</s0>
</fC03><fC03 i1="03" i2="X" l="ENG"><s0>Drug combination</s0>
</fC03><fC03 i1="03" i2="X" l="SPA"><s0>Asociación medicamentosa</s0>
</fC03><fC03 i1="04" i2="X" l="FRE"><s0>Chimiothérapie</s0>
</fC03><fC03 i1="04" i2="X" l="ENG"><s0>Chemotherapy</s0>
</fC03><fC03 i1="04" i2="X" l="SPA"><s0>Quimioterapia</s0>
</fC03><fC03 i1="05" i2="X" l="FRE"><s0>Efficacité traitement</s0>
</fC03><fC03 i1="05" i2="X" l="ENG"><s0>Treatment efficiency</s0>
</fC03><fC03 i1="05" i2="X" l="SPA"><s0>Eficacia tratamiento</s0>
</fC03><fC03 i1="06" i2="X" l="FRE"><s0>Homme</s0>
</fC03><fC03 i1="06" i2="X" l="ENG"><s0>Human</s0>
</fC03><fC03 i1="06" i2="X" l="SPA"><s0>Hombre</s0>
</fC03><fC03 i1="07" i2="X" l="FRE"><s0>Voie orale</s0>
</fC03><fC03 i1="07" i2="X" l="ENG"><s0>Oral administration</s0>
</fC03><fC03 i1="07" i2="X" l="SPA"><s0>Vía oral</s0>
</fC03><fC03 i1="08" i2="X" l="FRE"><s0>Parkinson maladie</s0>
</fC03><fC03 i1="08" i2="X" l="ENG"><s0>Parkinson disease</s0>
</fC03><fC03 i1="08" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
</fC03><fC03 i1="09" i2="X" l="FRE"><s0>Etude double insu</s0>
</fC03><fC03 i1="09" i2="X" l="ENG"><s0>Double blind study</s0>
</fC03><fC03 i1="09" i2="X" l="SPA"><s0>Estudio doble ciego</s0>
</fC03><fC03 i1="10" i2="X" l="FRE"><s0>Placebo</s0>
</fC03><fC03 i1="10" i2="X" l="ENG"><s0>Placebo</s0>
</fC03><fC03 i1="10" i2="X" l="SPA"><s0>Placebo</s0>
</fC03><fC03 i1="11" i2="X" l="FRE"><s0>Tolcapone</s0>
<s2>NK</s2>
<s2>FR</s2>
</fC03><fC03 i1="12" i2="X" l="FRE"><s0>Dopa</s0>
<s2>NK</s2>
<s2>FR</s2>
</fC03><fC03 i1="12" i2="X" l="ENG"><s0>Dopa</s0>
<s2>NK</s2>
<s2>FR</s2>
</fC03><fC03 i1="12" i2="X" l="SPA"><s0>Dopa</s0>
<s2>NK</s2>
<s2>FR</s2>
</fC03><fC03 i1="13" i2="X" l="FRE"><s0>Bensérazide</s0>
<s2>NK</s2>
<s2>FR</s2>
</fC03><fC03 i1="14" i2="X" l="FRE"><s0>Catechol methyltransferase</s0>
<s2>FE</s2>
<s4>INC</s4>
</fC03><fC07 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
</fC07><fC07 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
</fC07><fC07 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
</fC07><fC07 i1="02" i2="X" l="FRE"><s0>Enzyme</s0>
</fC07><fC07 i1="02" i2="X" l="ENG"><s0>Enzyme</s0>
</fC07><fC07 i1="02" i2="X" l="SPA"><s0>Enzima</s0>
</fC07><fC07 i1="03" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
</fC07><fC07 i1="03" i2="X" l="ENG"><s0>Cerebral disorder</s0>
</fC07><fC07 i1="03" i2="X" l="SPA"><s0>Encéfalo patología</s0>
</fC07><fC07 i1="04" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
</fC07><fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0>
</fC07><fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
</fC07><fC07 i1="05" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
</fC07><fC07 i1="05" i2="X" l="ENG"><s0>Degenerative disease</s0>
</fC07><fC07 i1="05" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
</fC07><fC07 i1="06" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
</fC07><fC07 i1="06" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
</fC07><fC07 i1="06" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
</fC07><fN21><s1>240</s1>
</fN21>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PascalFrancis/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001775 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 001775 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PascalFrancis
|étape= Curation
|type= RBID
|clé= Pascal:95-0422394
|texte= Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024 |  |
